Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd Key Recent Developments

Nov 21, 2022: SHIONOGI Integrated Report 2022 won silver award in the WICI Japan Integrated Report Award 2022
Oct 31, 2022: Shionogi announces 1st Half of Fiscal 2022 Financial Results
Oct 17, 2022: Shionogi and Hirakata City, Osaka sign partnership agreement for support and awareness-raising of infectious disease control
Oct 04, 2022: Shionogi and MPP enter Covid-19 antiviral licencing deal

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Shionogi & Co Ltd - Key Facts
Shionogi & Co Ltd - Key Employees
Shionogi & Co Ltd - Key Employee Biographies
Shionogi & Co Ltd - Major Products and Services
Shionogi & Co Ltd - History
Shionogi & Co Ltd - Company Statement
Shionogi & Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

Section 2 - Company Analysis

Company Overview
Shionogi & Co Ltd - Business Description
R&D Overview
Shionogi & Co Ltd - Corporate Strategy
Shionogi & Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Shionogi & Co Ltd - Strengths
Shionogi & Co Ltd - Weaknesses
Shionogi & Co Ltd - Opportunities
Shionogi & Co Ltd - Threats
Shionogi & Co Ltd - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
Shionogi & Co Ltd, Recent Deals Summary

Section 5 - Company’s Recent Developments

Nov 21, 2022: SHIONOGI Integrated Report 2022 won silver award in the WICI Japan Integrated Report Award 2022
Oct 31, 2022: Shionogi announces 1st Half of Fiscal 2022 Financial Results
Oct 17, 2022: Shionogi and Hirakata City, Osaka sign partnership agreement for support and awareness-raising of infectious disease control
Oct 04, 2022: Shionogi and MPP enter Covid-19 antiviral licencing deal
Aug 29, 2022: Shionogi Continuously selected for inclusion in all ESG Indices Adopted by the Government Pension Investment Fund (GPIF)
Jul 01, 2022: Notice regarding the launch of the new SHIONOGI Group Brand
May 23, 2022: Shionogi announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment
Apr 05, 2022: Shionogi partners with Cloudera to accelerate R&D and achieve data-driven innovation in pharmaceuticals
Apr 05, 2022: AMR Action Fund launches investments to promote innovation to overcome AMR
Mar 16, 2022: Shionogi announces the results of comprehensive maternal and child health support activities undertaken in Kenya under the “Mother to Mother SHIONOGI Project” - Health of Maasai Mothers and Children has Improved -

Section 6 - Appendix

Methodology
Ratio Definitions
About the Publisher
Contact the Publisher
Disclaimer

List of Tables

Shionogi & Co Ltd, Key Facts
Shionogi & Co Ltd, Key Employees
Shionogi & Co Ltd, Key Employee Biographies
Shionogi & Co Ltd, Major Products and Services
Shionogi & Co Ltd, History
Shionogi & Co Ltd, Other Locations
Shionogi & Co Ltd, Subsidiaries
Shionogi & Co Ltd, Joint Venture
Shionogi & Co Ltd, Key Competitors
Shionogi & Co Ltd, Ratios based on current share price
Shionogi & Co Ltd, Annual Ratios
Shionogi & Co Ltd, Interim Ratios
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
Shionogi & Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Shionogi & Co Ltd, Performance Chart (2018 - 2022)
Shionogi & Co Ltd, Ratio Charts
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022